Regenxbio (RGNX) Net Equity Issued and Repurchased (2015 - 2026)
Regenxbio (RGNX) posted quarterly Net Equity Issued and Repurchased of $494000.0 for Q2 2017, down 99.39% quarter-over-quarter from $81.5 million in Q1 2017.
Powered by 
Analysis
Regenxbio (RGNX) Net Equity Issued and Repurchased (2015 - 2026) Analysis & Trends
Regenxbio's Net Equity Issued and Repurchased history runs 2 years deep, the most recent figure standing at $494000.0 for Q2 2017.
- In Q2 2017, Net Equity Issued and Repurchased changed N/A year-over-year to $494000.0; the TTM figure through Dec 2018 stood at $494000.0 (down 99.4% YoY), while the FY2018 annual figure was $189.7 million, up 131.38% from the prior year.
- Net Equity Issued and Repurchased for Q2 2017 stood at $494000.0, down from $81.5 million in the prior quarter.
- The five-year high for Net Equity Issued and Repurchased was $81.5 million in Q1 2017, with the low at $494000.0 in Q2 2017.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Equity Issued and Repurchased (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 49.20 Mn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | - |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | 141.90 Mn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | - |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | - |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | - |
| 10 | Regenxbio | 472.74 Mn | 367.22 Mn | - | 18.90 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 18.90 Mn |
| Mar 31, 2024 | 131.10 Mn |
| Jun 30, 2017 | 494,000.00 |
| Mar 31, 2017 | 81.50 Mn |
| Jun 30, 2015 | 41.98 Mn |
| Mar 31, 2015 | 26.02 Mn |